论文部分内容阅读
目的:探讨托吡酯与左乙拉西坦单药治疗癫痫患者的临床价值。方法:选取湛江中心人民医院门诊2014年6月至2015年6月收治的癫痫患者76例,随机将患者分为A组和B组,每组38例,A组给予托吡酯片,B组给予左乙拉西坦片,治疗后18个月内进行随访,观察两组患者的治疗效果并进行评价。结果:A组的总有效率为94.7%,B组的总有效率为78.9%,A组的总有效率高于B组,差异具有统计学意义(P<0.05)。A组不良反应发生8例,不良反应发生率为13.2%;B组不良反应发生10例,不良反应发生率为34.2%,不良反应发生率B组高于A组,差异具有统计学意义(P<0.05)。结论:托吡酯和左乙拉西坦单药治疗癫痫在临床效果和药物不良反应上差异明显,可将托吡酯片作为癫痫临床治疗首选药物。
Objective: To investigate the clinical value of topiramate and levetiracetam monotherapy in patients with epilepsy. Methods: Seventy-six patients with epilepsy were enrolled in the outpatient department of Zhanjiang Central People’s Hospital from June 2014 to June 2015. The patients were randomly divided into group A and group B, with 38 patients in each group. Group A received topiramate and group B received left Etiracetam tablets, 18 months after treatment were followed up to observe the treatment of two groups of patients and evaluated. Results: The total effective rate was 94.7% in group A and 78.9% in group B, and the total effective rate in group A was higher than that in group B (P <0.05). A group of adverse reactions occurred in 8 cases, the incidence of adverse reactions was 13.2%; B group of adverse reactions occurred in 10 cases, the incidence of adverse reactions was 34.2%, the incidence of adverse reactions in group B was higher than in group A, the difference was statistically significant (P <0.05). Conclusion: Topiramate and levetiracetam monotherapy in the treatment of epilepsy in clinical effects and adverse drug reactions significantly different, topiramate tablets can be used as the preferred drug for the clinical treatment of epilepsy.